AII
BPMC

AGF Investments Inc’s Blueprint Medicines BPMC Stock Holding History

AGF Investments Inc’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,000
Closed -$206K – 725
2021
Q3 		$206K Buy
+2,000
New +$186K ﹤0.01% 530

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

AGF Investments Inc's BPMC Position: Q4 2021 in Review

AGF Investments Inc sold out of Blueprint Medicines (BPMC) in Q4 2021, closing a stake of 2,000 shares — an estimated $206K sold.

AGF Investments Inc first reported a position in BPMC in Q3 2021 and held it in 1 quarter. The position peaked at $206K in Q3 2021. 280 funds tracked by Wall St. Rank hold BPMC as of Q4 2021.

  • AGF Investments Inc reported no remaining Blueprint Medicines position as of Q4 2021 after selling out during the quarter.
  • AGF Investments Inc sold 2,000 Blueprint Medicines shares in Q4 2021, an estimated $206K.
  • AGF Investments Inc first reported a position in Blueprint Medicines in Q3 2021 and held it in 1 quarter.
  • AGF Investments Inc's Blueprint Medicines position peaked at $206K in Q3 2021.
  • 280 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2021.

Based on AGF Investments Inc's 13F filing for Q4 2021, filed 1 Feb 2022.